This review addresses the most recent advancements in the aspects of KRAS, the attributes of KRAS mutations in cancer patients, and its correlation with tumor immunity and emphasizes the immunomodulatory pathways in cancer and immunotherapeutic approaches to target KRAS-related mutations in different cancers. This evidence concerns the gene KRAS and cancer.